Martha Rumore, PharmD, JD, MS, LLM, FAPhA
Associate Professor, Social, Behavior and Administrative Sciences
Dr. Martha Rumore is a Fellow of the American Pharmacists Association and Associate Professor at Touro College of Pharmacy where she teaches Pharmaceutical Law and Drug Information. She also taught Drug Regulatory Affairs and Food, Drug Cosmetic Law at Long Island University College of Pharmacy. In 2016 she was appointed to the ACPE Board of Directors.
Dr. Martha Rumore is also presently an Oncology Pharmacist (alternating weekends for 22 years) at Beth Israel Medical Center, Mt. Sinai.
Dr. Martha Rumore is also presently Of Counsel at the law firm of Sorell, Lenna & Schmidt. She is admitted to the NY, NJ and DC bars and is registered to practice before the U.S. Patent & Trademark Office. Dr. Rumore focuses on pharmaceutical and medical device intellectual property including all aspects of patent law: prosecution, opinion work, litigation and transactional matters. Martha has authored freedom-to-operate, patentability, invalidity, infringement and non-infringement opinions, including opinions supporting Paragraph IV certification under the Hatch-Waxman Act.
She has over eight years of law firm experience counseling on early market opportunities for generic clients particularly in the area of Paragraph IV matters and has also prepared ANDAs and 510K applications. She has experience in all facets of ANDA litigation-expert witness reports, depositions, scientific document review, complaint and answer, motion practice. Representative generic cases she has handled include Glaxo v. Andrex Pharmaceuticals, Medpointe v. Hi-Tech Pharmacal (2nd chair), and Schwartz Pharmaceuticals v. Sun Pharma. She teaches Food, Drug & Cosmetic Law at Touro Law School.
LLM, Benjamin N. Cardozo School of Law New York, Intellectual Property, NY; 2003
JD, City University of New York, School of Law, NY; 2000
MS, Arnold & Marie Schwartz College of Pharmacy, Drug Information & Biomedical Communication, NY; 1990
PharmD, St. John’s University, NY; 1980
- Pharmaceutical/Chemical Patent Law
- Food, Drug Cosmetic Law
- Pharmacy Law
- Drug Information
- Hospital Pharmacy Management
- Medication Safety
- Food, Drug, Cosmetic Law
- Drug Information
Academic and Professional Honors
North Shore LIJ- 2014 Afternoon of Innovation Recognition, Project Demonstrated Costs Avoidance of over $2 million dollars from pharmacist interventions.
“Cost Avoidance Assessment of Pharmacist’s Interventions at a Metropolitan Pediatric Hospital”
New York Lawyers For Public Interest- Pro Bono Excellence Award 2008, For Medicare Rights Center Project
ACPE Board Member 2016-2022
Beth Israel Medical Center - June 1993 - present - Oncology Satellite Pharmacist
Cohen Children’s Medical Center of NY Jan 2012-May 2014
Assistant Director, Clinical & Educational Services
Director, Pediatric Medication Resource Center
Director, Pharmacy Student Experiential Programs
Secretary, P&T Committee
New York Presbyterian Hospital - Nov 2008-Jan 2012
Clinical Manager, Drug Information
ACPE Program Director
- Drug Information
- Pharmacy Law & Ethics
- Pharmacy Legislative Issues & Biomedical Regulatory Affairs
- Food, Drug, Cosmetic Law & Regulation
Rumore, Martha., Cobb, Elizabeth., Sullivan, Maureen., Wittman, Deborah. Biosimilars: Opportunities and Challenges for Nurse Practitioners. The Journal for Nurse Practitioners. Vol 12; 3; 2016. Pg 181-191.
Legal Aspects of Drug Information Practice. In Malone PM, Stanovich J., Kier K, Malone MJ (eds.) Drug Information: A Guide For Pharmacists. Norwalk, Connecticut, McGraw Hill, New York, 1996, pp. 169-186; 2nd ed. 2001 pp. 276-201; 3rd ed. 2005, pp. 411-457; 4th ed. 2011 pp. 505-553, 5th ed. 2014 pp. 503-568.
The Function, Evolution, and Historical Development of the Law. In Konnor D (ed.). Jurisprudence and Ethics for Pharmacists. New York, Hawthorne Press. 2008, pp. 1-16.
Patent, Trademark & Copyright Law. In Konnor D (ed.). Jurisprudence and Ethics for Pharmacists. New York, Hawthorne Press. 2008, pp. 125-149.
Impact of Liability and Cost Containment on the Drug Development Process, In Welling P & Lasagna L. (eds.). The Drug Development Process: Increasing Efficacy and Cost Effectiveness. New York, Marcel Dekker, 1996, pp. 45-78.
Rumore MM. Law Update- 2014. NYC Council of Hospital Pharmacists Newsletter. Scheduled Summer 2104.
Slattery E, Rumore MM, Douglas J., Seres DS. Three-in-one Versus Two-in-one Parenteral Nutrition In Adults: A Review. Nutrition Clin Pract. doi: 10.1177/0884533614533611; May 28, 2014.
Rumore MM, Houst B. Palytoxin Poisoning via Inhalation in Pediatric Siblings. Int. J Case Reports and Images. 2014; 5(7):501-504.
Rumore MM, Sussman R. Ceftriaxone Safety in the Pediatric Population. J Amer Pharm Assoc 54(2): e192 (March/April 2014).
Samide J, Rumore MM. Intravenous Acetaminophen Usage in Patients. J Amer Pharm Assoc 54(2): e197 (March/April 2014).
Guerra J, Ligniti E, Rumore MM. Palivizumab Performance Improvement Initiative in a Neonatal Intensive Care Unit Setting (Abstract). J Amer Pharm Assoc 54(2): e119 (March/April 2014).
Rumore MM. Post Caronia: Is a New Paradigm Needed for Off-Label Medication Usage? J Medical Marketing. 2013;13(4):212-220.
Houst B, Rumore MM, Ligniti E. Development of a Pediatric-Specific Medication Resource Center at a Metropolitan Children’s Hospital (Abstract). J Amer Pharm Assoc 53(2):71 (March/April 2013).
Rumore MM, Ligniti E, Schwartz R. Increasing HangTime for Premixed Solutions to 96 Hours: Phase I (Abstract) J Amer Pharm Assoc 53(2):85 (March/April 2013).
Rumore MM. Updates on Asthma Management. Pharmacy Frontlines. 2013:2(1):1.
Rumore MM. Inhalational Palytoxin Poisoning in Pediatric Siblings. The Clinical Courier. 2012 (Nov.):2(11):1.
Rumore MM. Pharmacy Law Update. Pharmacy Frontlines. 2012:1(6):1.
Patel M, Rumore MM. Anaphylaxis from TPA. Blood Coagulation & Fibrinolysis. 2012:23:568-570.
Patel Y, Rumore MM. Makena or Compounded 17P? (Letter to the Editor). P&T Journal. 2012:37(9):488-489.
Rumore MM. Clinical Practice Pearl. Cardiovascular Adverse Effects of Metoclopramide. Pharmacy Practice News. July 2012; 39:9, 35, 36.
Patel Y, Rumore MM. Hydroxyprogesterone Caproate Injection One Year Later: To Compound or Not to Compound- That is the Question? P&T Journal. 2012:37(7):405-411.
Rumore M., Vaidean G., Development of a Risk Assessment: Tool for Falls Prevention in Hospital Inpatients Based on the Medication Appropriateness Index (MAI) and Modified Beer’s Criteria. Innovations in Pharmacy. 2012;3(1):e1-12. Available at http://www.pharmacy.umn.edu/innovations/vol3no1/home.html.
Rumore M. Cardiovascular Adverse Effects of Metoclopramide- Review of the Literature. Int J Case Reports & Images. 2012;3(5):1-10.
Rumore M. Lee S, Wang S. Metoclopramide-Induced Cardiac Arrest: Case Report and Review of the Literature. Clinics and Practice. 2011;1:e83:174-176.
Rumore M, Roth M, Orfanos A. Dietary Tyramine Restriction For Hospitalized Patients on Linezolid: An Update. J. Amer Pharm. Assoc 51:249-50, (Mar/Apr. 2011).
Rumore M, Roth M, Orfanos A. Dietary Tyramine Restriction For Hospitalized Patients on Linezolid: An Update. J. Enteral & Parenteral Nutrition 25(3): 265-69, (June) 2010.
Rumore M, Kim K. Potential Role of Salicylates in Type 2 Diabetes. Annals Pharmacotherapy 44: 1207-21, (July/August) 2010.
Rumore M. The Hatch-Waxman Act-25 Years Later. Keeping the Pharmaceutical Scale Balanced. August 2009. Pharmacy Times. Generic Drug Supplement. August 2009, pp. 4-7, 20. Also published online August 15, 2009. Available at http://www.pharmacytimes.com/print.php?url=http://www.pharmacytimes.com/supplement
Rumore M, Colloca B. New Law Brings Changes to Medicare Part D, Pharmacy Times, January 2009, pp. 43-45.
Rumore M. Recent Trends in Lanham Act Litigation Involving Generic Substitution (Abstract). J. Amer. Pharm. Assoc., 48(2):288, 2008.
Rumore M, Safe Harbor or Pirate Cove? Merck v. Integra and Its Seeming Impact on International Research Activities. SciTech Lawyer 3(3):12-15, Winter 2007.
Restino L, Rumore MM. Safe Harbor or Uncharted Seas? Integra v. Merck Currents. N.J. Lawyer 14(20):1,6, 2005. .
Vepachedu S, Rumore M. Patent Protection and the Pharmaceutical Industry in the Indian Union. Intellectual Property Today 11:44-46, Oct. 2004.
Vepachedu S, Rumore M. The Pharmaceutical Industry and the New Patent Regime in the Indian Union. Andhra J. Indust. News, Issue 10, Jan. 10, 2005. Available at http://www.vepachedu.com/AJIN/January2005.html.
Rumore M. Determinants of Patenting in the U.S. Pharmaceutical Industry. Published at the website of Scully, Scott, Murphy & Presser. Available at http://email@example.com.
Rumore M. Determinants of Patenting in the U.S. Pharmaceutical Industry Based on Recent CAFC Case Law. J. Amer. Pharm. Assoc. 44:298, Mar/April 2004.
Rumore M. Ranbaxy Pharmaceuticals v. Apotex. Redefining Claim Drafting and Patent Prosecution Under Festo. ABA Intellectual Property Newsletter. 22:12-15, Summer 2004.
Rumore M. Direct to Consumer Advertising of Prescription Drugs- Emerging Legal and Regulatory Issues. Hospital Pharmacy, 39:158-1068, Nov. 2004.
Rumore M. Analysis of Potential Waxman-Hatch Revisions-Keeping the Pharmaceutical Scale Balanced. Pharmacy Law Annual 2002. Winner of the 2002 Larry Simonsmeir Legal Writing Competition.
Interests/Hobbies/Life Outside of Work
Adventure travel, Yoga